5-Azacytidine inhaled dry powder formulation profoundly improves pharmacokinetics and efficacy for lung cancer therapy through genome reprogramming

BACKGROUND: Epigenetic therapy through demethylation of 5-methylcytosine has been largely ineffective in treating lung cancer, most likely due to poor tissue distribution with oral or subcutaneous delivery of drugs such as 5-azacytidine (5AZA). An inhalable, stable dry powder formulation of 5AZA was...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuehl, Philip J., Tellez, Carmen S., Grimes, Marcie J., March, Thomas H., Tessema, Mathewos, Revelli, David A., Mallis, Larry M., Dye, Wendy W., Sniegowski, Tyler, Badenoch, Aaron, Burke, Michael, Dubose, Devon, Vodak, David T., Picchi, Maria A., Belinsky, Steven A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156464/
https://www.ncbi.nlm.nih.gov/pubmed/32103148
http://dx.doi.org/10.1038/s41416-020-0765-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156464/
https://www.ncbi.nlm.nih.gov/pubmed/32103148
http://dx.doi.org/10.1038/s41416-020-0765-2

Ejemplares similares